NEW YORK, May 28, 2025 -- Biotia, a leader in infectious disease diagnostics powered by genomics and AI, is proud to announce that its tool, BIOTIA-DX Resistance, achieved the highest prediction accuracy in the 2025 CAMDA (Critical Assessment of Massive Data Analysis) Antimicrobial Resistance Challenge.
Hosted as part of the ISMB 2025 conference, CAMDA brings together top researchers from around the world to benchmark advanced computational tools on real-world datasets. Biotia's submission outperformed all other participating methods in predicting Antimicrobial Resistance profiles from metagenomic data, demonstrating the clinical and research power of our proprietary platform.
"This recognition at CAMDA highlights our commitment to innovation in combating antimicrobial resistance," said David Danko, Chief Technology Officer at Biotia. "BIOTIA-DX Resistance is part of our broader mission to deliver actionable insights through genomic analysis and help clinicians make better-informed treatment decisions."
Biotia will present its results at ISMB 2025 in Liverpool this July. The CAMDA presentation will detail the methods and performance behind the BIOTIA-DX Resistance pipeline and its implications for the future of Antimicrobial Resistance surveillance and diagnostics.
For more information about Biotia and our platform, visit www.biotia.io or contact us at info@biotia.io. For more information about BIOTIA-DX Resistance see the technical note at www.biotia.io/technical-notes or come see Biotia present this work at CAMDA@ISMB.
This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology.
